ImmuRAID-LL2 mouse antibody fragment linked to technetium-99m data

The Morris Plains, N.J., company presented data from an ongoing Phase I/II trial in the U.S. and Europe. The product had a sensitivity and accuracy of 86 percent in 43 patients. Positive predictive value was 100 percent, the company reported at the meeting of the European Associates of Nuclear Medicine in Germany.

No adverse effects were seen; in patients receiving 1 mg or less. There were no immune responses to the imaging agent. ...